Biocon receives CDSCO approval for its Liraglutide drug in India
Biocon Limited, a global biopharmaceutical company, has announced that it has received regulatory approval in India for its Liraglutide drug substance. Its wholly owned subsidiary, Biocon Pharma Limited, has also secured approval for the Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge) from the Central Drugs Standard Control Organisation (CDSCO).
The product is a generic version of Victoza®, used as an adjunct to diet and exercise to improve glycemic control in adults, adolescents, and children aged 10 years and older with Type 2 Diabetes Mellitus that is not adequately managed.
Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd, commented, 'The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes. India has one of the highest number of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further. The approval enables us to address a critical need by making this drug available, and aligns with Biocon's mission to provide affordable, lifesaving medications to those who need it the most. We are now gearing up to launch the product expeditiously through our commercialization partners in India''
This approval was granted under the CDSCO's recently introduced 101 route. This regulatory pathway allows for the recognition of approvals issued by referenced and established foreign regulatory agencies, thereby facilitating faster access to critical medicines in India.
Glucagon-like peptide-1 (GLP-1) therapies, including Liraglutide, are being recognized as a growing segment in diabetes management. Biocon has stated its intent to expand its portfolio in this category as part of its future business strategy.
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New York Post
2 hours ago
- New York Post
5 foods that naturally stimulate the ‘Ozempic hormone' — without drugs
Want to shed pounds without getting poked? Your fork might be the fix. While GLP-1 drugs like Ozempic and Wegovy have taken the weight-loss world by storm, there are some everyday foods that offer similar benefits naturally — no needle required. 'No one food is a magic bullet for anything, but getting a balanced diet rich in nutrition-dense foods is a great way to manage your appetite and feelings of being full,' Dr. Amir Khan, a general practitioner, said in an Instagram video. Advertisement Khan broke down five foods to add to your diet if you're looking to naturally boost your levels of GLP-1, the hunger-controlling hormone that these trendy drugs are designed to mimic. An added bonus: These foods are also packed with nutrients that benefit your whole body, not just your waistline. But first: what is GLP-1? Advertisement GLP-1 is a hormone released by the small intestine after you eat, according to the Cleveland Clinic. It plays several key roles in how the body processes food, including triggering insulin production to turn meals into energy and lower blood sugar levels. 5 About 12% of US adults have tried a GLP-1 drug. millaf – Advertisement It also suppresses glucagon, a hormone that raises blood sugar, and slows stomach emptying, which helps you feel fuller for longer. GLP-1 drugs mimic this natural process by curbing appetite and reducing food intake, often leading to weight loss. But according to Khan, some kitchen staples can produce similar effects. #1 Eggs Packed with protein and monounsaturated fats, eggs have been shown to help boost GLP-1 secretion. Advertisement 'Egg whites in particular are thought to be beneficial to GLP-1 release,' Khan said. 5 Eggs may even help trigger the release of GLP-1 and other satiety hormones. Mara Zemgaliete – A 2016 study compared a bagel breakfast to one with three eggs. The egg meal led to lower blood sugar after eating, less hunger, and reduced food intake over the next 24 hours. #2 Certain nuts Almonds, pistachios, and walnuts may help boost GLP-1 thanks to their fiber, protein, and healthy fats. These nutrients work together to slow digestion, leading to a more steady rise in blood sugar and improving insulin sensitivity. #3 High-fiber grains Grains like oats, barley and whole wheat are packed with soluble fiber, which dissolves in water and forms a gel-like substance in your gut. 5 Soluble fiber, found in oats, barley, and rye, slows down the digestion process. baibaz – Advertisement This gel slows digestion and the release of glucose into your bloodstream, preventing sugar spikes and triggering GLP-1 release. #4 Olive oil 'Studies suggest unsaturated fats, like those in olive oil, stimulate GLP-1 release better than saturated fats found in butter,' Khan explained. Olive oil also slows carbohydrate digestion, helping prevent rapid blood sugar spikes. Advertisement Its polyphenols and vitamin E provide antioxidant and anti-inflammatory benefits that support hormone regulation — including GLP-1. A 2021 review found that a Mediterranean diet rich in olive oil led to higher post-meal GLP-1 levels, improved insulin sensitivity, and lower blood sugar compared to diets high in saturated fats. #5 Some vegetables Veggies like Brussels sprouts, broccoli and carrots are loaded with fiber, which helps regulate blood sugar. Advertisement Gut bacteria break down that fiber into short-chain fatty acids, which Khan says signal gut cells to release GLP-1 into the bloodstream. 5 Vegetables are high in fiber, vitamins and minerals, which can help regulate blood sugar and GLP-1 levels. Wolfilser – A 2022 study found that eating vegetables before carbs significantly improved glucose and GLP-1 levels in people with type 2 diabetes — especially an hour after eating. America's weight problem Advertisement About one in eight US adults have tried a GLP-1 drug, according to a 2024 KFF poll. Among them, nearly four in 10 say weight loss was the primary reason. Obesity is an epidemic in America, with more than two in five adults and nearly one in five kids and teens classified as obese, per the CDC. The health fallout is huge. Obesity is a risk factor for a wide range of chronic conditions, including heart disease, type 2 diabetes, osteoarthritis, sleep apnea, kidney disease and even several cancers. But it's not just physical. Obesity can take a toll on mental health, with research showing it increases the risk of developing low self-esteem, depression, eating disorders and chronic stress. On top of that, people with obesity often face bias at school and work, taking a serious toll on their quality of life.
Business Upturn
4 hours ago
- Business Upturn
Brigade Enterprises launches Rs 2,100 crore residential project ‘Morgan Heights' in Chennai
Brigade has launched a new residential project in Chennai called Brigade Morgan Heights , located along the Sholinganallur–Medavakkam road. Spread across 14.7 acres, the community is designed to offer a modern, comfortable lifestyle, with a mix of 2, 3, and 4 BHK apartments. The homes range up to 2,599 sq. ft. in size, and the entire development will house around 1,250 units. What stands out about the location is its proximity to the upcoming Classical Tamil Institute Metro Station—just 150 meters away. This is expected to offer easy access to nearby IT parks like Elcot, Wipro, and Cognizant, which are all within a 10-minute drive. The project is being developed under a Joint Development Agreement and has a total built-up potential of about 2.2 million square feet. Brigade Morgan Heights is being positioned as a sustainable, nature-friendly space. The community features solar panels, rainwater harvesting, and organic waste processing systems. Green areas and landscaped spaces are planned throughout the layout, including bird-friendly zones and natural lighting-focused design. Residents will have access to a 40,000 sq. ft. clubhouse that includes a gym, yoga terrace, co-working zones, sports courts, a swimming pool, and more. The project also includes spaces meant for social gatherings and quiet corners for seniors or evening strolls. In short, it's being designed as a self-contained community that balances comfort, connectivity, and a touch of green. Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Business Upturn
12 hours ago
- Business Upturn
Novo Nordisk: Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA
By GlobeNewswire Published on June 21, 2025, 04:38 IST Higher dose of Wegovy® provided average weight loss of 21% in people with obesity – with a third achieving 25% or more – according to data presented at ADA Results from the phase 3b STEP UP trial showed that a higher dose of Wegovy ® (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo 1 (semaglutide 7.2 mg) delivered 21% weight loss in people with obesity, with a third of participants losing 25% or more of their weight, compared to placebo Safety and tolerability of the higher dose of Wegovy ® (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) 1 (semaglutide 7.2 mg) was consistent with the currently approved dose (semaglutide 2.4 mg) The STEP UP data add to the existing evidence base on the value of Wegovy® in delivering significant weight loss and health gains for people living with obesity Bagsværd, Denmark, 21 June 2025 – Novo Nordisk today presented the results from the phase 3b STEP UP trial in people with obesity without diabetes at the American Diabetes Association (ADA) Scientific Sessions, in Chicago, US. In the STEP UP trial, the higher dose of Wegovy® (semaglutide 7.2 mg) demonstrated a mean weight loss of 21%, with a third of participants losing 25% or more of their body weight compared to placebo at 72 weeks.1 'The STEP UP trial demonstrated that we can increase the dose of semaglutide and achieve greater weight loss than previously seen, and in line with semaglutide's established safety profile. This may offer another option to people who do not attain their weight goals,' said Sean Wharton, lead study author and medical director of the Wharton Medical Clinic, Canada. 'We are already aware that semaglutide can have health benefits for people with heart disease, liver disease, knee osteoarthritis, type 2 diabetes and prediabetes. These findings help to give patients with obesity more options for improvements in their weight and overall health.' STEP UP co-primary endpoints at 72 weeks *1 : semaglutide 7.2 mg semaglutide 2.4 mg PlaceboWeight loss 20.7% 17.5% 2.4% 5% or more weight loss 93.2% 92.5% 35.7% When evaluating the effect of treatment regardless of treatment adherence, people receiving semaglutide 7.2 mg achieved 18.7% weight loss vs 3.9% with placebo, and 90.7% achieved 5% or more weight loss with semaglutide 7.2 mg vs 36.8% on placebo. 'With these results, semaglutide reaffirms its significant weight loss for people with obesity. The STEP UP trial delivers a substantial weight loss of over 20%, in addition to health benefits previously demonstrated with semaglutide,' said Ludovic Helfgott, executive vice president of Product & Portfolio Strategy at Novo Nordisk. 'As pioneers in obesity, we continue to develop new innovative treatments to fit the needs and preferences of people living with obesity. This includes maximising the value of semaglutide for individuals, healthcare systems and society, and developing a new oral formulation of Wegovy® that, pending FDA approval, can become the first GLP-1 pill to offer double-digit weight loss.' In the STEP UP trial, semaglutide 7.2 mg demonstrated a well-tolerated safety profile consistent with previous Novo Nordisk semaglutide trials.1 The most common adverse events were gastrointestinal, and the vast majority were mild to moderate during dose escalation and diminished over time, consistent with the GLP-1 class.1 In STEP UP, 3.3% of people treated with semaglutide 7.2 mg discontinued due to gastrointestinal adverse events, compared to 2.0% with semaglutide 2.4 mg and 0% with placebo.1 Novo Nordisk expects to file the higher dose of Wegovy® for a label update in the EU in the second half of 2025, followed by regulatory submissions in other markets where Wegovy® is already approved. STEP UP selected confirmatory secondary endpoints at 72 weeks * 1 : semaglutide 7.2 mg semaglutide 2.4 mg Placebo10% or more weight loss 86.0% 77.6% 20.0%15% or more weight loss 70.4% 57.5% 7.9%20% or more weight loss 50.9% 35.1% 2.9% 25% or more weight loss 33.2% 16.7% 0% * Based on the trial product estimand: treatment effect if all people adhered to treatment. About the STEP UP trials Novo Nordisk has completed two trials, STEP UP and STEP UP T2D, investigating the efficacy and safety of semaglutide 7.2 mg in people with obesity with or without type 2 diabetes. The 72-week STEP UP trial was a randomised, double-blinded, parallel-group, placebo-controlled, superiority trial designed to evaluate the efficacy and safety of semaglutide 7.2 mg compared to semaglutide 2.4 mg and placebo as an adjunct to lifestyle intervention. The trial included 1,407 adults with a BMI ≥30 kg/m2 without diabetes. The primary objective was to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. Key confirmatory secondary endpoints included the number of participants achieving 10%, 15%, 20% and 25% weight loss, respectively. The 72-week STEP UP T2D trial investigated semaglutide 7.2 mg in 512 adults with obesity and type 2 diabetes, with the primary objective to demonstrate superiority of semaglutide 7.2 mg against placebo on weight loss. About Wegovy® Semaglutide 2.4 mg is marketed under the brand name Wegovy®. In the EU, Wegovy® is indicated as an adjunct to a reduced calorie diet and increased physical activity for weight management in adults with a BMI of 30 kg/m2 or greater (obesity) or adults with a BMI of 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. In the EU, Wegovy® is also indicated for paediatric patients aged 12 years and older with an initial BMI at the 95th percentile or greater for age and gender (obesity) and body weight above 60 kg. The clinical section of the label also includes data on Wegovy® major adverse cardiovascular events (MACE) risk reduction, improvements in HFpEF-related symptoms and physical function, as well as pain reduction related to knee osteoarthritis. In the US, Wegovy® is indicated in combination with a reduced calorie diet and increased physical activity to reduce the risk of MACE in adults with established cardiovascular disease and either obesity or overweight, as well as to reduce excess body weight and maintain weight reduction long term in paediatric patients aged 12 years and older with obesity and in adults with obesity or with overweight in the presence of at least one weight-related comorbid condition. About Novo Nordisk Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. For more information, visit , Facebook , Instagram , X , LinkedIn and YouTube . Contacts for further information References Wharton, S, et al. (2025). Once-weekly semaglutide 7.2 mg in adults with obesity: the randomised, controlled, phase 3b STEP UP trial. 1966-LB poster. American Diabetes Association (ADA) 85th Scientific Sessions, Chicago, US, June 20 – 23, 2025.17. Attachment Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
